Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.

Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. J Immunol. 2018 10 01; 201(7):1967-1974.

View in: PubMed

subject areas

Antineoplastic Agents
Cell Differentiation
Cell Proliferation
Cells, Cultured
Cytokines
Gene Expression Profiling
Humans
Immunization
Interferon-gamma
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphocyte Activation
Receptors, Antigen, T-Cell
Receptors, Antigen, T-Cell, alpha-beta
Th1 Cells
Treatment Outcome
Tumor Microenvironment

authors with profiles

Yusuke Nakamura